TLX591-Tx

Drug

Related News

Novartis Expands US Radioligand Manufacturing as Telix Reports Cancer Trial Data

Jun 08, 2026

Novartis expands US radioligand manufacturing with new Texas and North Carolina facilities to bolster domestic production of cancer treatments. Telix Pharmaceuticals reports positive Phase 3 prostate cancer trial data and maintains 2026 revenue guidance of US$950-970 million.

Telix says ProstACT Global Phase 3 Part 1 met primary objectives

May 12, 2026

Telix said Part 1 of the ProstACT Global Phase 3 study met its primary objectives for TLX591-Tx in mCRPC. The company reported acceptable safety, no new safety signals and progression plans for Part 2.